Hepatic parenchymal enhancement during triple-phase helical CT: Can it be used to predict which patients with breast cancer will develop hepatic metastases?
Dh. Sheafor et al., Hepatic parenchymal enhancement during triple-phase helical CT: Can it be used to predict which patients with breast cancer will develop hepatic metastases?, RADIOLOGY, 214(3), 2000, pp. 875-880
Citations number
22
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
PURPOSE: To evaluate the efficacy of hepatic enhancement characteristics fo
r identification of patients with breast cancer who are at risk for future
hepatic metastases.
MATERIALS AND METHODS: Triple-phase helical computed tomography (CT) was pe
rformed in 60 patients with known breast cancer without visible hepatic met
astases. Peak hepatic attenuation and enhancement, and attenuation and enha
ncement at 25 and 30 seconds were obtained. Ratios of hepatic attenuation o
r;enhancement at 25 and 30 seconds to peak hepatic attenuation or enhanceme
nt were calculated. A Wilcoxon rank sum test was used to compare patients w
ith and those without subsequent hepatic metastases.
RESULTS: During a mean 18-month follow-up, 18 patients (30%) developed hepa
tic metastases. Decreases in peak hepatic attenuation and enhancement and i
ncreases in hepatic attenuation and enhancement ratios at 25 and 30 seconds
were seen in patients who developed metastases compared with those who did
not (P < .05). When corrected for chemotherapy interval, these differences
were not statistically significant. Using a threshold value of 0.40 or mor
e for the enhancement ratio at 30 seconds resulted in sensitivity of 28%, s
pecificity of 92%, and accuracy of 55%.
CONCLUSION: Patients with breast cancer who develop subsequent hepatic meta
stases have higher relative hepatic arterial perfusion during triple-phase
CT; however, after correction for chemotherapy interval, this difference wa
s not statistically significant. Threshold values cannot be used reliably t
o identify patients who will develop metastases.